

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5184139

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
NANOSCALE COMBINATORIAL SYNTHESIS, INC.	07/12/2012
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	PHARMACYCLICS, INC.
<b>Street Address:</b>	995 EAST ARQUES AVENUE
<b>City:</b>	SUNNYVALE
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94085
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16035449
<b>Application Number:</b>	16110999
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)832-7000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617-832-1000
<b>Email:</b>	patentdocketing@foleyhoag.com, fgrizey@foleyhoag.com
<b>Correspondent Name:</b>	FOLEY HOAG, LLP
<b>Address Line 1:</b>	155 SEAPORT BOULEVARD
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02210
<b>ATTORNEY DOCKET NUMBER:</b>	PIR-85384; PIR-85389
<b>NAME OF SUBMITTER:</b>	FRAN GRIZEY
<b>SIGNATURE:</b>	/Fran Grizey/
<b>DATE SIGNED:</b>	10/11/2018
<b>Total Attachments: 2</b>	
source=Assignment Nano to Phar Inc (3)#page1.tif	
source=Assignment Nano to Phar Inc (3)#page2.tif	

**CORPORATE TO CORPORATE ASSIGNMENT**

Docket Number 25922-853.101

WHEREAS, NANOSCALE COMBINATORIAL SYNTHESIS, INC. ("NANOSYN") (hereinafter "Assignor"), owns the entire right, title and interest in and to the inventions disclosed in the Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:







**CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR**

☐ for which a United States patent application is executed on even date herewith;  
☒ for which Application No. 61/655,381 was filed on June 4, 2012 in the United States Patent Office;  
☐ for which Application No. \_\_\_\_\_ was filed on \_\_\_\_\_ in the U.S. Receiving Office of the Patent Cooperation Treaty;  
☐ for which Application No. \_\_\_\_\_ was filed on \_\_\_\_\_ in the \_\_\_\_\_ Patent Office; and/or  
☐ for which an application was filed upon which a United States Patent issued on \_\_\_\_\_, as U.S. Patent No. \_\_\_\_\_ (hereinafter "Application(s)").

WHEREAS, Pharmacyclics, Inc., a corporation of the State of Delaware, having a place of business at 995 East Arques Avenue, Sunnyvale, CA 94085, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Inventions, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by the inventor(s) of said Inventions, and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee its entire right, title and interest (a) in and to said Inventions and said Applications, including the right to claim priority to said Inventions and said Applications; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty, or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).
2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.
4. Said Assignor hereby warrants and represents that the Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
5. Said Assignor hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

<b>CORPORATE TO CORPORATE ASSIGNMENT</b>	Docket Number 25922-853.101		
<p>6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.</p> <p>IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.</p> <p style="text-align: center;"><b>ASSIGNOR</b></p> <table><tr><td>Date: <u>07/12/2012</u></td><td>By:  Name: Olga Issakova, Ph.D. Title: Executive Vice President</td></tr></table>		Date: <u>07/12/2012</u>	By:  Name: Olga Issakova, Ph.D. Title: Executive Vice President
Date: <u>07/12/2012</u>	By:  Name: Olga Issakova, Ph.D. Title: Executive Vice President		
<p>RECEIVED AND AGREED TO BY ASSIGNEE:</p> <table><tr><td>Date: <u>13 July 2012</u></td><td>By:  Name: David J. Lounsbury Title: Chief Scientific Officer</td></tr></table>		Date: <u>13 July 2012</u>	By:  Name: David J. Lounsbury Title: Chief Scientific Officer
Date: <u>13 July 2012</u>	By:  Name: David J. Lounsbury Title: Chief Scientific Officer		